drugset / Trial / NCT01935635

A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB

NCT01935635 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate whether HB-Vac Activated-DCs Combined With Peg-IFN or NAs has more efficacy than Peg-IFN or NAs alone in the treatment of chronic hepatitis B patients

Timeline

Start
2015-01
Primary completion
2019-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HPDCs-T Unknown 200000 cells Intravenous
Subject HPDCs-T Unknown 1e+06 cells Intravenous